Indivior Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Indivior Pharmaceuticals (INDV).

Price Target Range — 11 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$38Upside to Avg. PT+4.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$43→$45
Aug 5, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$46→$43
Jun 18, 2026	Barclays	Glen Santangelo	Initiate	Overweight	$46
Jan 12, 2026	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$35→$48
Oct 31, 2025	Piper Sandler	David Amsellem	PT Raise	Overweight	$27→$41
Oct 30, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$28→$35
Aug 27, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$27→$34
Aug 6, 2025	HC Wainwright & Co.	Brandon Folkes	Initiate	Buy	$28
Jul 22, 2025	Jefferies	Dennis Ding	Assumes	Buy	$20
Jun 30, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$15→$22
Mar 6, 2025	Piper Sandler	David Amsellem	PT Cut	Overweight	$16→$13
Oct 25, 2024	Piper Sandler	David Amsellem	PT Raise	Overweight	$15→$16
Oct 11, 2024	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$20→$16
Oct 11, 2024	Piper Sandler	David Amsellem	PT Cut	Overweight	$22→$15
Sep 13, 2024	Piper Sandler	David Amsellem	Maintained	Overweight	$22
Jul 23, 2024	Piper Sandler	David Amsellem	Initiate	Overweight	$22
Jul 10, 2024	Craig-Hallum	Chase Knickerbocker	PT Cut	Buy	$37→$24
Apr 3, 2024	Craig-Hallum	Chase Knickerbocker	Initiate	Buy	$37

Analyst Ratings News

PRO
Barclays Maintains Overweight on Indivior Pharmaceuticals, Raises Price Target to $45

Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and raises the price target from $43 to $45.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43

Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and lowers the price target from $46 to $43.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46

Barclays analyst Glen Santangelo initiates coverage on Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight rating and announces Price Target of $46.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $48

HC Wainwright & Co. analyst Brandon Folkes maintains Indivior (NASDAQ:INDV) with a Buy and raises the price target from $35 to $48.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Indivior, Raises Price Target to $41

Piper Sandler analyst David Amsellem reiterates Indivior (NASDAQ:INDV) with a Overweight and raises the price target from $27 to $41.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $35

HC Wainwright & Co. analyst Brandon Folkes maintains Indivior (NASDAQ:INDV) with a Buy and raises the price target from $28 to $35.

Benzinga Newsdesk

Indivior Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Indivior Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Indivior Pharmaceuticals, Raises Price Target to $45

PRO
Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43

PRO
Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46

PRO
HC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $48

PRO
Piper Sandler Reiterates Overweight on Indivior, Raises Price Target to $41

PRO
HC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $35

People Also Watch

People Also Watch

Indivior Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Indivior Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Indivior Pharmaceuticals, Raises Price Target to $45

PROBarclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43

PROBarclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46

PROHC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $48

PROPiper Sandler Reiterates Overweight on Indivior, Raises Price Target to $41

PROHC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $35

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Indivior Pharmaceuticals, Raises Price Target to $45

PRO
Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43

PRO
Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46

PRO
HC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $48

PRO
Piper Sandler Reiterates Overweight on Indivior, Raises Price Target to $41

PRO
HC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $35